Abstract
Complestatin, a bicyclo hexapeptide from Streptomyces, was isolated as a possible regulator of neuronal cell death. In this study, we report an anti-apoptotic activity of complestatin and its underlying molecular mechanism. Complestatin blocked TRAIL (TNF-related apoptosis-inducing ligand)-induced apoptosis and activation of caspase-3 and -8 at micromolar concentration levels without inhibiting the catalytic activities of these caspases. Complestatin potently induced a rapid and sustained AKT/PKB activation and Bad phosphorylation, resulting in inhibition of mitochondrial cytochrome c release. These anti-apoptotic activities of complestatin were significantly abrogated in cells expressing dominant negative AKT/PKB. Taken together, our results suggest that complestatin prevents apoptotic cell death via AKT/PKB-dependent inhibition of the mitochondrial apoptosis signal pathway. The novel property of complestatin may be valuable for developing new pharmaceutical means that will control unwanted cell death.
| Original language | English |
|---|---|
| Pages (from-to) | 193-204 |
| Number of pages | 12 |
| Journal | Biochemical and Biophysical Research Communications |
| Volume | 313 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2004.01.2 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- AKT/PKB
- Apoptosis
- Caspases
- Complestatin
- TRAIL
Fingerprint
Dive into the research topics of 'Complestatin prevents apoptotic cell death: Inhibition of a mitochondrial caspase pathway through AKT/PKB activation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver